They may also be used as a combination therapy with immune checkpoint blockades such as anti-CTLA4, anti-LAG3 and anti-TIGIT in addition to anti-PD-1 investigated in this study to achieve long-term and more durable effects against tumor growth and progression. Here, PDCD1 is linked to neoplasm.